Regarding "HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer"

Oncologist. 2020 Nov;25(11):e1818. doi: 10.1634/theoncologist.2020-0385. Epub 2020 Aug 13.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Biliary Tract Neoplasms* / genetics
  • Biliary Tract Neoplasms* / surgery
  • Humans
  • Prognosis
  • Receptor, ErbB-2

Substances

  • Receptor, ErbB-2